The FDA approval of pembrolizumab for patients with TMB >10 mut/Mb: was it a wise decision? No
- PMID: 32771305
- DOI: 10.1016/j.annonc.2020.07.001
The FDA approval of pembrolizumab for patients with TMB >10 mut/Mb: was it a wise decision? No
Conflict of interest statement
Disclosures VP reports research funding from Arnold Ventures, royalties from Johns Hopkins Press, Medscape, honoraria from grand rounds/lectures from universities, medical centers, non-profits, and professional societies, consulting from United Healthcare, speaking fees from eviCore, and others from plenary session podcast has Patreon backers. AA reports personal fees from BMS, AstraZeneca, MSD, Pfizer, Roche, Takeda, and Boehringer outside the submitted work.
Comment on
-
The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians.Ann Oncol. 2020 Sep;31(9):1115-1118. doi: 10.1016/j.annonc.2020.07.002. Epub 2020 Aug 5. Ann Oncol. 2020. PMID: 32771306 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
